Ward Hadaway advises on healthcare investment
20th June, 2013
CORPORATE experts from Ward Hadaway have provided advice to The North West Fund for Biomedical, managed by SPARK Impact, on its investment in Perfectus Biomed, a company which uses bacteria testing to help develop new healthcare products.
Based at the Sci-Tech Park in Daresbury, near Warrington, Perfectus Biomed specialises in the testing of bacteria which are linked to chronic non-healing wounds, failed medical implants and catheter infections.
It conducts testing to help its clients develop antimicrobial agents and devices suitable for use in areas including wound care, medical implants, dentistry and contact lenses.
The company will use the £50,000 from The North West Fund, together with £50,000 from venture capital company Midven, to expand its research team, implement a marketing strategy and invest in equipment.
Melanie Yeomans, Partner in the Corporate team at Ward Hadaway, provided advice to SPARK Impact on the deal.
Melanie said: “We are delighted to have assisted SPARK Impact on another investment from The North West Fund for Biomedical.
“Perfectus Biomed’s work has applications across a wide range of medical and healthcare sectors.”
This is the latest in a series of investments from The North West Fund for Biomedical which Ward Hadaway has advised on.
The North West Fund for Biomedical is part of the £155m North West Fund, financed jointly by the European Regional Development Fund and the European Investment Bank.
Please note that this briefing is designed to be informative, not advisory and represents our understanding of English law and practice as at the date indicated. We would always recommend that you should seek specific guidance on any particular legal issue.
This page may contain links that direct you to third party websites. We have no control over and are not responsible for the content, use by you or availability of those third party websites, for any products or services you buy through those sites or for the treatment of any personal information you provide to the third party.
